These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 31748853

  • 1. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
    Yang L, Li H, Xia W, Quan C, Zhou L, Geng D, Li Y.
    Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
    [Abstract] [Full Text] [Related]

  • 2. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Küker W, Chandratre S, Vincent A, Palace J.
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    Du Q, Shi Z, Chen H, Zhang Y, Wang J, Qiu Y, Zhao Z, Zhang Q, Zhou H.
    J Neuroimmunol; 2021 Apr 15; 353():577494. PubMed ID: 33515897
    [Abstract] [Full Text] [Related]

  • 9. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
    Yan Y, Li Y, Fu Y, Yang L, Su L, Shi K, Li M, Liu Q, Borazanci A, Liu Y, He Y, Bennett JL, Vollmer TL, Shi FD.
    Sci China Life Sci; 2016 Dec 15; 59(12):1270-1281. PubMed ID: 26920678
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C, Chen B, Tao R, Chen M, Ma X, Shang K, Wu LJ, Wang W, Bu BT, Tian DS.
    Mult Scler Relat Disord; 2019 Oct 15; 35():1-4. PubMed ID: 31276911
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
    Duan Y, Zhuo Z, Li H, Tian DC, Li Y, Yang L, Gao C, Zhang T, Zhang X, Shi FD, Barkhof F, Liu Y.
    J Neurol Neurosurg Psychiatry; 2021 Jul 15; 92(7):709-716. PubMed ID: 33687975
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
    Chien C, Scheel M, Schmitz-Hübsch T, Borisow N, Ruprecht K, Bellmann-Strobl J, Paul F, Brandt AU.
    Mult Scler; 2019 Dec 15; 25(14):1926-1936. PubMed ID: 30475082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.